{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:03:27Z","timestamp":1780938207653,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>NF2<\/jats:italic>\n                    -related schwanomatosis (\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN) (previously Neurofibromatosis 2) as characterised by bilateral vestibular schwannomas (VS) was first described in 1822. However, due to the erroneous conflation of individuals with bilateral eighth nerve tumours with von Recklinghausen disease (currently Neurofibromatosis 1, NF1) in 1917 the literature was confusing for much of the 20th century. Even when the conditions were separated officially in 1987 (with separate localisation of the genes),\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN remained classified as a neurofibromatosis despite the tumours pathognomonic for NF1, neurofibromas, not being a feature of NF2-schwannomatosis. It is only in 2022 that\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN was correctly delineated as a schwannomatosis. The epidemiology of\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN has only been possible to delineate after the separation of\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN from the much more frequent nerve sheath predisposing tumour condition NF1. Two research groups have published on the birth prevalence and population prevalence of\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN in the UK and Finland. The most highly ascertained assessment of\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN cases from the Manchester region of England (population 4.8\u00a0million) gave a diagnostic prevalence of 1 in 50,500 and calculated birth prevalences of 1 in 27,956 respectively. However, an updated prevalence across England in 2024 (population 55\u00a0million) gave a prevalence of at least 1 in 58,000.\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN usually presents with bilateral vestibular schwannoma, but can present with meningioma or spinal tumour or ophthalmic features before a VS diagnosis or with a unilateral VS and other tumours and rarely with a unilateral VS alone. Molecular testing is now extremely helpful in confirming the diagnosis of mosaic (present in up to 50% of de novo cases) versus germline\n                    <jats:italic>NF2<\/jats:italic>\n                    and distinguishing from other tumour predisposition conditions especially in childhood or cases with less common presentation. This chapter summarises the clinical epidemiology of\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN differentiating the condition from the overlapping non\n                    <jats:italic>NF2-<\/jats:italic>\n                    SWN.\n                  <\/jats:p>","DOI":"10.1007\/s10689-025-00504-5","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:16:30Z","timestamp":1761725790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["History and clinical epidemiology of NF2-related schwannomatosis"],"prefix":"10.1007","volume":"24","author":[{"given":"D. Gareth","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"504_CR1","unstructured":"Sandifort E (1777) De duram quodam corpusculo nervo auditorio adherente. Obs Anat Pathol. 1, 116\u2013120"},{"key":"504_CR2","first-page":"393","volume":"18","author":"JH Wishart","year":"1822","unstructured":"Wishart JH (1822) Case of tumours in the skull, dura mater, and brain. Edinb Med Surg J 18:393\u2013397","journal-title":"Edinb Med Surg J"},{"key":"504_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/brain\/60.1.85","volume":"60","author":"C Worster-Drought","year":"1937","unstructured":"Worster-Drought C, Dickson WEC, McMenemy WH (1937) Multiple meningeal and perineural tumours with analogous changes in the glia and ependyma (neurofibromatosis). Brain 60:88\u2013117","journal-title":"Brain"},{"key":"504_CR4","unstructured":"Von Recklinghausen, F. (1882) Ueber die multiplen Fibroma der Haut und ihre Beziehung zu den multipelen Neuromen. Berlin, A. Hirschwald."},{"key":"504_CR5","volume-title":"Tumours of the nervus acusticus and the syndrome of the cerebello-pontine angle","author":"H Cushing","year":"1917","unstructured":"Cushing H (1917) Tumours of the nervus acusticus and the syndrome of the cerebello-pontine angle. Saunders, Philadelphia"},{"key":"504_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/bmj.1.3093.496","volume":"1","author":"A Feeling","year":"1920","unstructured":"Feeling A, Ward E (1920) A familial form of acoustic tumour. BMJ 1:496\u2013497","journal-title":"BMJ"},{"key":"504_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/archneurpsyc.1930.02220080050005","volume":"23","author":"WJ Gardner","year":"1930","unstructured":"Gardner WJ, Frazier CH (1930) Bilateral acoustic neurofibromas: a clinical study and field survey of a family of five generations with bilateral deafness in thirty eight members. Arch Neurol Psychiatry 23:266\u2013302","journal-title":"Arch Neurol Psychiatry"},{"key":"504_CR8","volume-title":"A clinical pathological and genetic study of multiple neurofibromatosis","author":"FW Crowe","year":"1956","unstructured":"Crowe FW, Schull WJ, Neal JV (1956) A clinical pathological and genetic study of multiple neurofibromatosis. Charles C. Thomas, Springfield, Illinois"},{"key":"504_CR9","first-page":"603","volume":"84","author":"DGR Evans","year":"1992","unstructured":"Evans DGR, Huson S, Donnai D et al (1992) A clinical study of type 2 neurofibromatosis. Quart J Med 84:603\u2013618","journal-title":"Quart J Med"},{"key":"504_CR10","first-page":"73","volume":"7","author":"PF Young","year":"1971","unstructured":"Young PF, Eldridge R, Nager GT et al (1971) Hereditary bilateral acoustic neuroma (central neurofibromatosis). Birth Defects Orig Artic Ser 7:73\u201386","journal-title":"Birth Defects Orig Artic Ser"},{"key":"504_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1212\/WNL.30.8.851","volume":"30","author":"WR Kanter","year":"1980","unstructured":"Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T (1980) Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology 30:851\u2013859","journal-title":"Neurology"},{"key":"504_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0092-8674(87)90534-4","volume":"49","author":"BR Seizinger","year":"1987","unstructured":"Seizinger BR, Rouleau GA, Ozelius LG et al (1987) Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 49:589\u2013594","journal-title":"Cell"},{"key":"504_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/329246a0","volume":"329","author":"G Rouleau","year":"1987","unstructured":"Rouleau G, Seizinger BR, Wertelecki W et al (1987) Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329:246\u2013248","journal-title":"Nature"},{"key":"504_CR14","unstructured":"National Institutes of Health Consensus Development Conference Statement on Neurofibromatosis. (1987). Neurofibromatosis Research newsletter 3: 3\u20136."},{"key":"504_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","volume":"111","author":"SM Huson","year":"1988","unstructured":"Huson SM, Harper PS, Compston DAS (1988) Von Recklinghausen neurofibromatosis: a clinical and population based study in southeast Wales. Brain 111:1355\u20131381","journal-title":"Brain"},{"key":"504_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/jmg.36.3.197","volume":"36","author":"JM McGaughran","year":"1999","unstructured":"McGaughran JM, Harris DI, Donnai D et al (1999) A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 36:197\u2013203","journal-title":"J Med Genet"},{"key":"504_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","volume":"113","author":"NIH Conference statement","year":"1990","unstructured":"NIH Conference statement (1990) Neurofibromatosis 1 (von Recklinghausen disease) and neurofibromatosis (bilateral acoustic neurofibromatosis). Ann Intern Med 113:39\u201352","journal-title":"Ann Intern Med"},{"issue":"1","key":"504_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","volume":"278","author":"DH Gutmann","year":"1997","unstructured":"Gutmann DH, Aylsworth A, Carey JC (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1):51\u201357","journal-title":"JAMA"},{"key":"504_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Troffater","year":"1993","unstructured":"Troffater JA, MacCollin MM, Rutter JL et al (1993) A novel Moesin-, Ezrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791\u2013800","journal-title":"Cell"},{"key":"504_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515\u2013521","journal-title":"Nature"},{"key":"504_CR21","first-page":"486","volume":"51","author":"SA Narod","year":"1992","unstructured":"Narod SA et al (1992) Neurofibromatosis type 2 appears to be a genetically homogenous disease. Am J Hum Genet 51:486\u2013496","journal-title":"Am J Hum Genet"},{"issue":"2","key":"504_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/ng.2855","volume":"46","author":"A Piotrowski","year":"2014","unstructured":"Piotrowski A, Xie J, Liu YF et al (2014) Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 46(2):182\u2013187","journal-title":"Nat Genet"},{"issue":"2","key":"504_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1212\/WNL.0000000000001129","volume":"84","author":"MJ Smith","year":"2014","unstructured":"Smith MJ, Isidor B, Beetz C et al (2014) Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology 84(2):141\u2013147","journal-title":"Neurology"},{"key":"504_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/jmg.29.12.847","volume":"29","author":"DGR Evans","year":"1992","unstructured":"Evans DGR, Huson SM, Donnai D, Neary W, Newton V, Blair V, Harris R (1992) A genetic study of type 2 neurofibromatosis: II guidelines for genetic counselling. J Med Genet 29:847\u2013852","journal-title":"J Med Genet"},{"issue":"11","key":"504_CR25","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","volume":"59","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Wallace AJ et al (2002) Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology 59(11):1759\u20131765","journal-title":"Neurology"},{"issue":"1","key":"504_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","volume":"88","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Bowers NL, Bulman M et al (2017) Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 88(1):87\u201392","journal-title":"Neurology"},{"issue":"7","key":"504_CR27","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41436-018-0384-y","volume":"21","author":"DG Evans","year":"2019","unstructured":"Evans DG, King AT, Bowers NL et al (2019) Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med 21(7):1525\u20131533","journal-title":"Genet Med"},{"issue":"9","key":"504_CR28","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24(9):1967\u20131977. https:\/\/doi.org\/10.1016\/j.gim.2022.05.007","journal-title":"Genet Med"},{"issue":"9","key":"504_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaneurol.2017.1406","volume":"74","author":"ON Pathmanaban","year":"2017","unstructured":"Pathmanaban ON, Sadler KV, Kamaly-Asl ID et al (2017) Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults. JAMA Neurol 74(9):1123\u20131129","journal-title":"JAMA Neurol"},{"issue":"4","key":"504_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/lary.27554","volume":"129","author":"DG Evans","year":"2019","unstructured":"Evans DG, Wallace AJ, Hartley C et al (2019) Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene. Laryngoscope 129(4):967\u2013973. https:\/\/doi.org\/10.1002\/lary.27554","journal-title":"Laryngoscope"},{"issue":"6","key":"504_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jmedgenet-2014-102973","volume":"52","author":"DG Evans","year":"2015","unstructured":"Evans DG, Freeman S, Gokhale C et al (2015) Bilateral vestibular schwannomas in older patients: NF2 or chance? J Med Genet 52(6):422\u2013424. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102973","journal-title":"J Med Genet"},{"key":"504_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajmg.1320520411","volume":"52","author":"DM Parry","year":"1994","unstructured":"Parry DM, Eldridge R, Kaiser-Kupfer M et al (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450\u2013451","journal-title":"Am J Med Genet"},{"issue":"2","key":"504_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/neuros\/nyx374","volume":"83","author":"AT King","year":"2018","unstructured":"King AT, Rutherford SA, Hammerbeck-Ward C et al (2018) High-grade glioma is not a feature of Neurofibromatosis type 2 in the unirradiated patient. Neurosurgery 83(2):193\u2013196","journal-title":"Neurosurgery"},{"issue":"6","key":"504_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1440-1789.2012.01306.x","volume":"32","author":"C Hagel","year":"2012","unstructured":"Hagel C, Stemmer-Rachamimov AO, Bornemann A et al (2012) Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology 32(6):611\u2013616","journal-title":"Neuropathology"},{"key":"504_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/adc.81.6.496","volume":"81","author":"DGR Evans","year":"1999","unstructured":"Evans DGR, Birch JM, Ramsden R (1999) Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496\u2013499","journal-title":"Arch Dis Child"},{"key":"504_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2024-110065","author":"C Forde","year":"2024","unstructured":"Forde C, Smith MJ, Burghel GJ et al (2024) NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study. J Med Genet. https:\/\/doi.org\/10.1136\/jmg-2024-110065","journal-title":"J Med Genet"},{"issue":"5","key":"504_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/archdischild-2017-313154","volume":"103","author":"G Anand","year":"2018","unstructured":"Anand G, Vasallo G, Spanou M et al (2018) Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Arch Dis Child 103(5):463\u2013469","journal-title":"Arch Dis Child"},{"issue":"1","key":"504_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000519143","volume":"65","author":"B Emmanouil","year":"2022","unstructured":"Emmanouil B, Wasik M, Charbel Issa P et al (2022) Structural abnormalities of the central retina in Neurofibromatosis Type 2. Ophthalmic Res 65(1):77\u201385. https:\/\/doi.org\/10.1159\/000519143","journal-title":"Ophthalmic Res"},{"issue":"1","key":"504_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/WNO.0000000000000675","volume":"39","author":"SL Painter","year":"2019","unstructured":"Painter SL, Sipkova Z, Emmanouil B et al (2019) Neurofibromatosis type 2-related eye disease correlated with genetic severity type. J Neuroophthalmol 39(1):44\u201349. https:\/\/doi.org\/10.1097\/WNO.0000000000000675","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"504_CR40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/ajmg.a.38177","volume":"173","author":"CF Rustad","year":"2017","unstructured":"Rustad CF, Dahl HM, Bowers NL et al (2017) Neurofibromatosis type 2: multiple intra-dermal tumors in a toddler. Am J Med Genet A 173(5):1447\u20131449. https:\/\/doi.org\/10.1002\/ajmg.a.38177","journal-title":"Am J Med Genet A"},{"key":"504_CR41","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jmg.29.12.841","volume":"29","author":"DGR Evans","year":"1992","unstructured":"Evans DGR, Huson S, Donnai D et al (1992) A genetic study of type 2 neurofibromatosis in the north west of England and the UK: prevalence, mutation rate, fitness and confirmation of maternal gene effect. J Med Genet 29:841\u2013846","journal-title":"J Med Genet"},{"issue":"2","key":"504_CR42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C et al (2010) Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. Am J Med Genet 152A(2):327\u2013332","journal-title":"Am J Med Genet"},{"issue":"11","key":"504_CR43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","volume":"89","author":"DG Evans","year":"2018","unstructured":"Evans DG, Bowers NL, Tobi S et al (2018) Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry 89(11):1215\u20131219","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"504_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DG Evans","year":"2005","unstructured":"Evans DG, Moran A, King A et al (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26(1):93\u201397","journal-title":"Otol Neurotol"},{"key":"504_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.54.1.71","volume":"54","author":"J Antinheimo","year":"2000","unstructured":"Antinheimo J, Sankila R, Carpen O et al (2000) Population based analysis of sporadic and NF2-associated meningiomas and schwannomas. Neurology 54:71\u201376","journal-title":"Neurology"},{"key":"504_CR46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","volume":"135","author":"E Uusitalo","year":"2015","unstructured":"Uusitalo E, Lepp\u00e4virta J, Koffert A et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135:904\u2013906. https:\/\/doi.org\/10.1038\/jid.2014.465","journal-title":"J Invest Dermatol"},{"issue":"1","key":"504_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41436-019-0598-7","volume":"22","author":"DG Evans","year":"2020","unstructured":"Evans DG, Hartley CL, Smith PT et al (2020) Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genet Med 22(1):53\u201359","journal-title":"Genet Med"},{"issue":"7","key":"504_CR48","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/jmg.2006.047753","volume":"44","author":"DG Evans","year":"2007","unstructured":"Evans DG, Ramsden RT, Shenton A et al (2007) Mosaicism in neurofibromatosis type 2: an update of risk based on uni\/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 44(7):424\u2013428","journal-title":"J Med Genet"},{"key":"504_CR49","first-page":"69","volume":"55","author":"D Bourn","year":"1994","unstructured":"Bourn D, Carter SA, Evans DGR et al (1994) A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet 55:69\u201373","journal-title":"Am J Hum Genet"},{"key":"504_CR50","first-page":"727","volume":"63","author":"DGR Evans","year":"1998","unstructured":"Evans DGR, Trueman L, Wallace A et al (1998) Mosaicism in classical NF2: a common mechanism for sporadic disease in tumour prone syndromes? Am J Hum Genet 63:727\u2013736","journal-title":"Am J Hum Genet"},{"key":"504_CR51","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/hmg\/7.13.2051","volume":"7","author":"L Kluwe","year":"1998","unstructured":"Kluwe L, Mautner VF (1998) Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 7:2051\u20132055","journal-title":"Hum Mol Genet"},{"key":"504_CR52","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1086\/301633","volume":"61","author":"L Jacoby","year":"1997","unstructured":"Jacoby L, Jones D, Davis K et al (1997) Molecular analysis of the NF2 tumor suppressor in schwannomatosis. Am J Hum Genet 61:1293\u20131302","journal-title":"Am J Hum Genet"},{"issue":"4","key":"504_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1086\/513207","volume":"80","author":"TJ Hulsebos","year":"2007","unstructured":"Hulsebos TJ, Plomp AS, Wolterman RA et al (2007) Germline mutation of INI1\/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80(4):805\u2013810","journal-title":"Am J Hum Genet"},{"key":"504_CR54","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI130206","volume":"130","author":"B Rivera","year":"2020","unstructured":"Rivera B, Nadaf J, Fahiminiya S et al (2020) Dgcr8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. J Clin Invest 130:1479\u20131490","journal-title":"J Clin Invest"},{"issue":"4","key":"504_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","volume":"49","author":"A Wilding","year":"2012","unstructured":"Wilding A, Ingham SL, Lalloo F et al (2012) Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet 49(4):264\u2013269","journal-title":"J Med Genet"},{"key":"504_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1086\/342716","volume":"71","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Aeschilman D et al (2002) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71:715\u2013723","journal-title":"Am J Hum Genet"},{"key":"504_CR57","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/jmedgenet-2015-103290","volume":"52","author":"A Hexter","year":"2015","unstructured":"Hexter A, Jones A, Joe H et al (2015) Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet 52:699\u2013705","journal-title":"J Med Genet"},{"issue":"10","key":"504_CR58","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","volume":"54","author":"D Halliday","year":"2017","unstructured":"Halliday D, Emmanouil B, Pretorius P et al (2017) Genetic severity score predicts clinical phenotype in NF2. J Med Genet 54(10):657\u2013664","journal-title":"J Med Genet"},{"issue":"1","key":"504_CR59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.a.34359","volume":"158A","author":"JO Blakeley","year":"2012","unstructured":"Blakeley JO, Evans DG, Adler J et al (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 158A(1):24\u201341. https:\/\/doi.org\/10.1002\/ajmg.a.34359","journal-title":"Am J Med Genet A"},{"issue":"6","key":"504_CR60","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1128\/MCB.01392-08","volume":"29","author":"SS Houshmandi","year":"2009","unstructured":"Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH (2009) The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol 29(6):1472\u20131486","journal-title":"Mol Cell Biol"},{"issue":"8","key":"504_CR61","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/neuonc\/noq012","volume":"12","author":"S Ammoun","year":"2010","unstructured":"Ammoun S, Cunliffe CH, Allen JC et al (2010) ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 12(8):834\u2013843. https:\/\/doi.org\/10.1093\/neuonc\/noq012","journal-title":"Neuro Oncol"},{"issue":"2","key":"504_CR62","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M et al (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122(2):313\u2013320. https:\/\/doi.org\/10.1007\/s11060-014-1710-0","journal-title":"J Neurooncol"},{"issue":"5","key":"504_CR63","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/neuonc\/nov200","volume":"18","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Plotkin SR (2016) Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 18(5):624\u2013638. https:\/\/doi.org\/10.1093\/neuonc\/nov200","journal-title":"Neuro Oncol"},{"issue":"4","key":"504_CR64","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/nop\/npv065","volume":"3","author":"KA Morris","year":"2016","unstructured":"Morris KA, Golding JF, Axon PR et al (2016) Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncol Pract 3(4):281\u2013289. https:\/\/doi.org\/10.1093\/nop\/npv065","journal-title":"Neuro-Oncol Pract"},{"issue":"7","key":"504_CR65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/neuonc\/noaa284","volume":"23","author":"C Forde","year":"2021","unstructured":"Forde C, King AT, Rutherford SA et al (2021) Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol 23(7):1113\u20131124. https:\/\/doi.org\/10.1093\/neuonc\/noaa284","journal-title":"Neuro Oncol"},{"key":"504_CR66","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Central Nervous System Cancers. Version 2.2025. All rights reserved. Accessed September 8, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org."}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00504-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:02:39Z","timestamp":1765011759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00504-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00504-5","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"79"}}